KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Total Non-Current Liabilities (2020 - 2025)

Ginkgo Bioworks Holdings' Total Non-Current Liabilities history spans 6 years, with the latest figure at $588.2 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities fell 8.78% year-over-year to $588.2 million; the TTM value through Dec 2025 reached $588.2 million, down 8.78%, while the annual FY2025 figure was $588.2 million, 8.78% down from the prior year.
  • Total Non-Current Liabilities reached $588.2 million in Q4 2025 per DNA's latest filing, down from $612.2 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $780.3 million in Q1 2023 to a low of $61.8 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $540.2 million, with a median of $594.2 million recorded in 2025.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 535.75% in 2022, then fell 29.55% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $467.6 million in 2021, then soared by 65.06% to $771.9 million in 2022, then dropped by 29.55% to $543.8 million in 2023, then increased by 18.59% to $644.8 million in 2024, then dropped by 8.78% to $588.2 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Total Non-Current Liabilities are $588.2 million (Q4 2025), $612.2 million (Q3 2025), and $600.1 million (Q2 2025).